Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idalopirdine PET Study in Alzheimer's Disease
NCT03307993Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: 5-HT6 Receptor Occupancy at Day 10 and Idalopirdine plasma concentration at Day 10. Started Sep 2017; status: terminated.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03307993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307993.